To evaluate the contributions of patient and treatment factors to overall expenditures and regional variation for initial treatment of localized prostate cancer (CaP) in the Medicare program.
P rostate cancer (CaP) imposes a substantial burden on patients, their caregivers, and the health care system. National costs for CaP care in 2010 were estimated at $12 billion in the United States. 1 As newer and more expensive technologies for surgery and radiotherapy have been readily adopted into clinical practice, [2] [3] [4] costs are likely to increase. In response to the concerns about rising costs of cancer care, including CaP care, there has been substantial interest in using a bundled payment for a specific episode of cancer care. 5, 6 The Center for Medicare & Medicaid Services recently announced the Bundled Payments for Care Improvement initiative, 7 where a "bundled" payment covers all services delivered across providers during a single episode of care. 8 This payment is designed to improve care coordination and reduce the use of inefficient services. However, setting up an appropriate bundled payment for all of the initial care in a CaP episode is challenging. 9 As a large variation may indicate inefficiency in the high-spending areas, bundled payments have the potential to reduce costs and improve quality in these areas. 10, 11 Understanding which factors are responsible for the highest expenditure variation can help policy makers prioritize efforts to create payment bundles for CaP care. Conceptually, several factors can lead to variation in CaP expenditures: first, patient and tumor characteristics affect treatment options and care patterns and, thus, expenditures. Second, expenditures can differ substantially among treatment options for localized CaP, including curative therapy (surgery or radiotherapy) and conservative management (active surveillance or watchful waiting). 12 Third, the propensity of adoption of costly modalities can exert a profound impact on treatment expenditures. To establish a bundled payment, it is important to know about how these different factors-patient clinical characteristics, treatment options, and the use of specific modality-contribute to overall CaP care expenditures, or variation across regions.
Furthermore, an important component of bundled payments is to hold multiple providers jointly accountable for the payment of a bundle of services. Bundled payments are perfectly suitable for CaP care, which involves collaborative efforts across multidisciplinary specialties. Thus, assessing which service (eg, surgery, radiation, biopsy, hormone therapy, and imaging) contributes more to expenditure variation across different providers can assist in setting up bundled payment schema. Although the prior literature has shown large variations in practice patterns for CaP care, [13] [14] [15] [16] [17] [18] [19] [20] few studies examined variations in expenditures. When studies examined this issue, they usually focused on services from one single treatment option. 21, 22 Hence, they provided limited information within the bundled payment framework. To date, little is known to what extent different services across specialties influence regional variation of overall CaP care expenditures.
To address these knowledge gaps, we estimated Medicare expenditures for the initial care of beneficiaries with newly diagnosed CaP across multiple providers. We then assessed the geographic variation of CaP-related expenditures across hospital referral regions (HRRs) and determined the contributions of treatment modality to CaP expenditures and variation. Finally, we categorized the expenditures according to the type of services to identify their relative impact on the expenditure variations.
METHODS

Model Overview
We first calculated CaP-related expenditures by computing the difference between the mean expenditures for cancer patients and for patients without cancer who are otherwise compatible, also known as the "net costs" approach. 23 We ranked HRRs according to CaP-related expenditures and grouped them into quintiles. We then used sequential models to determine the relative contribution of different factors to the overall expenditure variation in CaP care. We estimated service-specific CaP-related expenditures, including services of surgery, radiotherapy, and ancillary procedures (biopsy, hormone therapy, and imaging). We constructed the ranking by "net costs" rather than by total expenditures from cancer patients for 2 reasons: Prior literature has shown that a substantial proportion of older Americans are estimated to have at least 2 chronic physical or behavioral health conditions. 24 Using Medicare expenditure among CaP patients without subtracting expenditure among controls incorrectly assumes no Medicare expenditure for other comorbidities. Our approach could also address the issue of variation of expenditures for different diseases within an HRR, 25 because noncancer expenditures were teased out at each HRR level.
Data Source
We used the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. The SEER program collects information on patients' sociodemographic and tumor characteristics. Use of health services and the corresponding expenditures were derived from Medicare claims. The Yale Human Investigation Committee determined that this study did not directly involve human subjects.
Study Population
Using the SEER-Medicare database, our "case" group consisted of men who were newly diagnosed with localized CaP during 2005-2009 who had the following: known month of diagnosis, diagnosis not reported from autopsy or death certificate, continuous Medicare Parts A and B fee-forservice coverage from 2 years before diagnosis through 1 year after diagnosis, and known zip code of residence to be linked to HRRs as defined by the Dartmouth Atlas of Healthcare. 26, 27 We excluded patients who had a history of a prior or concurrent malignancy. We only included men who were 67 years of age or older at diagnosis to have 2 years of claims history before diagnosis to assess comorbidity. To reduce variability caused by low HRR volumes, we excluded data from HRRs with fewer than 25 patients during the study period.
Each man identified as a CaP "case" was 1:1 frequency matched to a man without cancer who served as a "control," using noncancer patients from the 5% random sample of Medicare beneficiaries residing in the same HRR. We created an index date for each "control" using the first day of a randomly selected month and year during 2005-2009 in which the control was alive and met the same enrollment criteria used for cases except for CaP diagnosis. "Cases" and "controls" were matched by age at the time of diagnosis for cases and the index date for controls (in quartiles), comorbidity (yes/no), race (white/black/other), year of diagnosis/index date, and precancer Medicare expenditure (from 18 mo through 6 mo before diagnosis/index date).
Elixhauser comorbidity conditions, adapting an approach that requires the International Classification of Diseases, 9th revision (ICD-9) diagnosis code to appear on an inpatient claim or Z2 outpatient claims >30 days apart during the time period 24 months to 3 months before diagnosis or index date. 28 Tumor characteristics included stage, prostate specific antigen level, and Gleason score, as reported by SEER. Treatment type and modality were identified from claims based on ICD-9 diagnosis and procedure codes and Healthcare Common Procedure Coding System codes (online supplementary material, Supplemental Digital Content 1, http:// links.lww.com/MLR/A755 for a list of treatment type and identified modality). Treatment intensity was defined as the percentage of patients receiving curative treatment, either surgery or radiotherapy.
Estimation of Medicare Spending
We defined initial phase of care as the period from 2 months prior through 12 months after CaP diagnosis/index date, consistent with the prior literature. 29 Medicare claims files including inpatient, outpatient, physician, home health, durable medical equipment, and hospice services during the initial phase of care were used to estimate CaP initial treatment expenditures. We adjusted for inflation 30 and geographic price differences. 31, 32 All expenditures were expressed in 2009 US dollars.
Statistical Analysis
We estimated the CaP-related expenditure for each HRR by calculating the difference in total Medicare expenditure for cases and for controls, using hierarchical generalized linear models (HGLMs) with a log link function and g distribution. Because there was heterogeneity in the effect of age between the "cases" and "controls" groups, we used separate risk adjustment models for these 2 groups. We Winsorized total expenditures by assigning the 97.5th percentile value to data above the 97.5th percentile to eliminate the influence of extreme values. [33] [34] [35] We calculated the expected mean CaP-related expenditure per patient for HRR i as the difference of the mean expected expenditures of the cases in HRR i and the mean expected expenditures of the control in HRR i . Then, for HRR i , we estimated its adjusted per patient CaP-related expenditure as:
where We used sequential models to determine the relative contribution of different factors to the overall expenditure variation in CaP care (detailed in Appendix). We estimated an unconditional model with just an intercept (model 0). We then used a multivariate model to adjust for patient demo-graphics and tumor characteristics (model 1). Lastly, we sequentially added 4 sets of dichotomous variables that reflected the treatment received: receipt of any curative treatment (model 2); receipt of surgery and/or radiotherapy (2 dichotomous variables representing each treatment separately, model 3); receipt of ancillary procedures (model 4); and receipt of specific surgery or radiotherapy modalities [open surgery, laparoscopic surgery, external beam radiation therapy, intensity-modulated radiation therapy (IMRT), brachytherapy, proton beam radiotherapy, and stereotactic radiosurgery, model 5].
Using a similar approach but only limited to data from the "cases," we estimated Medicare expenditure on the major components of CaP care (ie, surgery, radiotherapy, and ancillary procedures). Because not all CaP patients received each of these treatments/services, many cases had 0 values on Z1 component expenditure. Therefore, we adapted the HGLMs by integrating them with 2-part models while allowing for correlated HRR random effects and accounting for the "semi-continuous" nature of these expenditure data. 36 We used these models to calculate for each CaP patient his "expected" Medicare expenditure based on his predicted probability of having nonzero expenditure and his predicted expenditure conditional on having nonzero expenditure (while setting the HRR random effect at 0). The adjusted per patient Medicare expenditure on each component of CaP care for HRR i was calculated as:
where O case;i;l , E case;i;l , and O case;l were defined as above except that they now refer to the lth component of cancer care. Estimated Medicare expenditures were then summarized across HRRs. We assigned the HRRs to 5 quintiles with each quintile accounting for one fifth of the CaP patients represented in the SEER-Medicare database. The degrees of regional variation in total expenditure, as well as in the different components of care, were evaluated by comparing the corresponding mean estimates across the HRR quintiles. Descriptive statistics were used to summarize the characteristics of patients stratified by HRR quintiles, using means for continuous variables and proportions for categorical variables. We calculated the mean expenditures on a specific service per service-received patient. Applying a point system developed by van Walraven et al, 37 we demonstrated similar distributions of comorbidities between the case and control groups across quintiles (online supplementary figures, Supplemental Digital Content 2, http://links.lww.com/MLR/A756). All data analysis was performed using SAS 9.2 (SAS Inc., Cary, NC).
RESULTS
There were 47,517 patients (mean age, 74 y) with newly diagnosed localized CaP during the study period in 95 HRRs ( Table 1 ). The unadjusted mean expenditure on CaP-related care per beneficiary was $15,700, ranging from $12,800 in quintile 1 to $18,900 in quintile 5 (difference = $6,100; 47.7% of the expenditure in quintile 1). Distributions of patients' demographics and tumor characteristics varied significantly across the quintiles. Patients in the highest expenditure areas were more likely to reside in metropolitan or higher income areas and to have less advanced disease (Table 1) . After adjusting for patient demographics and tumor characteristics, the mean expenditure on CaP-related care per beneficiary was $15,900: specifically, $1800 on surgery, $11,200 on radiotherapy, $1200 on biopsy, $500 on hormone therapy, and $300 on imaging (Table 2 ).
Explaining Geographic Differences
Sequentially adjusting for patient characteristics, treatment intensity, ancillary procedures, and treatment modalities reduced the differences in CaP-related expenditures between the highest and lowest quintiles (Fig. 1) . The difference between quintiles 5 and 1 was $6200 in model 0. After adjusting for demographics and tumor characteristics, the difference between quintiles 5 and 1 was still as high as $5700 (model 1), indicating that patients' characteristics only explained 8.4% of the difference. Adding an indicator for treatment intensity (model 2) reduced the size of the variation to $4400, which indicated that treatment intensity could explain an additional 21.2% of the original difference. When we specified surgery and radiotherapy, the difference between quintiles 5 and 1 was decreased to $4100 (model 3), explaining an additional 5.2% of the original difference. Including an expanded set of ancillary procedures explained (model 4) . The estimation of model 5, which further specified surgery and radiotherapy modalities, showed that the magnitude of the unexplained variation between quintiles 5 and 1 was substantially reduced to $2000, indicating that the specific treatment modality explained an additional 31.2% of the original difference. Still, 31.6% of the geographic variation could not be explained by the factors we evaluated.
Regional Variation in Utilization Patterns and Corresponding Expenditures
The spending on the individual type of services varied across CaP expenditure quintiles and contributed to the variation of total expenditures differently ( Table 2 ). Radiotherapy accounted for the largest portion of the expenditure variation across HRRs. The difference of spending on radiotherapy per CaP beneficiary between quintiles 5 and 1 was $5000. In contrast, spending variation in other services was a smaller driver of regional difference in total CaP expenditures. The difference of spending per CaP beneficiary between quintiles 5 and 1 on biopsy, imaging, or hormone therapy only contributed to <$200 of the total expenditure variation. Furthermore, HRRs with lower total expenditures had higher spending per CaP beneficiary on surgery than HRRs with higher total expenditures. Treatment intensity varied across quintiles of CaP expenditures, ranging from 56.3% of patients receiving curative treatment in the lowest spending quintile to 63.7% in the highest spending quintile (Table 3) . Compared with patients living in quintile 1 HRRs, patients living in quintile 5 HRRs were more likely to receive radiotherapy (57.8% vs. 46.5%), hormone therapy (37.6% vs. 32.9%), and imaging (61.5% vs. 48.9%), and were less likely to receive surgery (13.4% vs. 17.7%). Notably, the largest difference between quintiles 1 and 5 was the percentage of patients receiving IMRT (24.7% vs. 41.9%; P < 0.001 for all comparisons).
The mean service-specific expenditures per servicereceived patient across 5 quintiles demonstrated that radiotherapy expenditures were the key factor driving the regional variation (Fig. 2) . The mean expenditure on radiotherapy varied from $19,600 per radiated patient in quintile 1 areas to $24,400 per radiated patient in the quintile 5 areas, a difference of $4800. In contrast, the average expenditures of surgery or ancillary procedures among patients who received that service did not differ substantially among quintiles.
DISCUSSION
We identified substantial geographic variation in initial treatment expenditures among Medicare beneficiaries with localized CaP. Patient and tumor characteristics provided little explanatory power, whereas treatment intensity and the type of treatment modalities received were the main factors driving the observed variation. Our findings build upon prior work in important ways. We found that radiotherapy expenditures not only were the largest component of CaP-related spending overall but also accounted for the largest portion of regional variation. Highspending areas not only provided more radiotherapy services but also used more expensive radiotherapy modalities. In contrast, spending for surgery and ancillary procedures represented a small portion of the variation. Our results suggest that the use of radiotherapy and the cost per-radiated patient are the most important factors driving geographic variation in CaP costs.
Second, we have defined how specific components of CaP care contribute to cancer-related expenditures. Although recent cost-containment initiatives such as the Choosing Wisely Campaign have focused on reducing imaging costs, 38 our findings suggest that a decrease in imaging may not control CaP spending substantially. Similarly, there has been increas-ing concern about biopsy and pathology expenditures, 39 with some reports finding that unit costs are estimated as high as $1100 for prostate biopsy and $700 for pathology 40 ; yet, we found that biopsy and pathology costs contributed little to overall spending for CaP care. In contrast, we found that radiotherapy expenditures accounted for 70% of overall spending and such expenditures varied substantially, largely because of the variation in the percentage of patients receiving radiotherapy and the treatment modality. Although expensive radiotherapy modalities may provide advantages over conventional treatments, such as reducing the likelihood of treatment-related toxicity and tumor recurrence, 41 very lowrisk CaP patients may not benefit from these modalities as the probability of progression is low. Indeed, conservative management can provide an equitable outcome for these patients. Recent research has shown that the use of expensive treatment modalities has increased among CaP patients who were unlikely to achieve a survival benefit. 42 Thus, monitoring the use of advanced technologies for men with low-risk CaP is warranted and is closely aligned to the American Society for Radiation Oncology's (ASTRO's) top 5 list that suggests that physicians should avoid giving curative therapy without discussing active surveillance first. 43 Third, our study underscores the need for research examining expenditure variation for a specific disease. Examining geographic variation in expenditures across populations and including a variety of diseases, researchers found that medical spending was largely explained by disease burden. 44 Yet, when we focus on a specific disease, we find that comorbidities and tumor characteristics contribute little to this variation. Recent research has also shown that spending for different conditions within an HRR was not strongly correlated, suggesting variation in physician aggressiveness within an HRR. 25 Our research demonstrates that, even for a single condition, high total CaP spending areas did not necessarily have high use across all types of services, providing further insight regarding bundling payments for an episode of care.
The services provided by urologists and radiation oncologists counteract their impact on regional variation, as low-spending Medical Care Volume 52, Number 8, August 2014 Prostate Cancer Expenditure Variation areas had a relatively high usage rate of surgery but low usage rate of radiotherapy and vice versa in the high-spending areas. We acknowledge that integrated practices between urologists and radiation oncologists might have different effects on expenditure variations, as patients were more likely to receive IMRT when urologists acquired radiotherapy equipment. 45 Therefore, areas of particularly low surgical volume and high radiotherapy volume may represent the practice pattern of integrated urology and radiation oncology practices. As current health reform moves toward targeting clinical decision making units rather than entire geographic areas, our results indicate that reducing reimbursement for all providers in high-spending areas may unfairly penalize urologists who may have approached CaP treatment with equipoise. Similarly, increasing reimbursement for all providers in lowspending areas may unjustly reward urologists who may have been treating more patients who may have been candidates for active surveillance. Bundled payment without considering different strategies across providers would miss the opportunity to select high-value therapy, and bundled payment across relevant specialties should consider the spectrum of variation that each specialty stands.
Our study has several limitations. Our analyses are based on the SEER-Medicare population, which does not necessarily represent all Medicare beneficiaries. However, we expect that the variation may be even larger in the entire United States. 46 We acknowledge that the health status information may not be comprehensive as we only used claims to capture comorbidity. Nevertheless, our results, identifying the key contributors to expenditure variation, are unlikely to change substantially as the SEER program does provide detailed cancer characteristics. Our case-control approach attempted to reduce unmeasured bias regarding expenses for treating diseases other than CaP. We acknowledge that our analysis did not address some unmeasured factors. We might have underestimated the magnitude of the variation in spending on each service across different areas as the quintile is ranked by total expenditure, not by the expenditure of each service. Notably, we still found substantial variation in radiotherapy expenditures. Finally, our study did not assess the association between an area's spending on indicators of its quality of care, the long-term spending for CaP care, and clinical outcomes, as well as not addressing some important factors such as hospital and physician characteristics on overall variations. Future research is warranted.
In summary, our findings of expenditure variations provide insights for policy makers to develop a Medicare value-based payment system. First, for localized CaP care, patient demographics and tumor characteristics were not a major driver of the expenditure variation. Both the receipt of any curative treatment and the expenditures of services are influential drivers of the overall expenditures. Second, radiotherapy expenditures accounted for 70% of overall spending and accounted for majority of geographic variation. To develop a bundles payment for CaP care, policy makers should target radiotherapy payment first. Guidelines and/or incentives for appropriate use of expensive modalities are necessary to reduce regional variation in CaP treatment expenditures. Third, expenditures on surgery and radiotherapy in particular are substantial. As active surveillance is one of the treatment options for low-risk CaP patients, motivating these patients to forgo active treatment implies potential savings without sacrificing clinical effectiveness. Future research should examine the long-term expenditures for conservative management, which could advance our knowledge on the magnitude of cost saving, and may potentially assist in developing a financial incentive to encourage active surveillance for appropriate population.
APPENDIX Sequential Models to Determine the Relative Contribution of Different Factors
For the jth patient clustered within HRR i , where i = 1, 2, y, 95 and j = 1, 2, y, n i , we calculated the "expected" Medicare expenditure for each beneficiary j as the predicted expenditure conditional on the HRR random effect being equal to 0. We calculated the expected mean CaP-related expenditure per patient for HRR i as the difference of the mean expected expenditures of the cases in HRR i and the mean expected expenditures of the control in HRR i . We assigned the 95 HRRs to 5 quintiles (k; k = 1-5) based on their mean CaP-related expenditure per patient in the null model. We then calculated the mean expenditure in quintile k where the estimated CaP-related expenditure of HRR i was weighted by n i (the number of patients in HRR i ) in the quintile k. These processes were calculated iteratively for each model. We specify our sequential models as following:
Model 0: Null model-only included an intercept and the HRR random effect. Model 1: Adjusted for patient demographics and tumor characteristics, including age, comorbidity, race, year of diagnosis, urban/rural residency, median household income at ZIP code, prostate-specific antigen level, Gleason score, and stage. 
